Insmed to Present at the Leerink Swann Global Healthcare Conference
04 Février 2014 - 2:15PM
Marketwired
Insmed to Present at the Leerink Swann Global Healthcare Conference
MONMOUTH JUNCTION, NJ--(Marketwired - Feb 4, 2014) - Insmed
Incorporated (NASDAQ: INSM), a biopharmaceutical company focused on
developing an inhaled anti-infective to treat patients battling
serious lung diseases in orphan indications that are often
life-threatening, today announced that members of the Company's
executive management team will be presenting at the Leerink Swann
Global Healthcare Conference taking place February 12-13, 2014 at
the Waldorf Astoria Hotel in New York City.
Will Lewis, President and CEO, will present a corporate overview
on February 12th at 8:50 a.m. Eastern time. Mr. Lewis'
presentation will be webcast live on the internet and can be
accessed by visiting the Investor Relations section of the
Company's website at www.insmed.com. A replay of the webcast will
be archived on the Insmed website for 90 days following the
presentation.
About Insmed
Insmed Incorporated is a biopharmaceutical company dedicated to
improving the lives of patients battling serious lung diseases.
Insmed is focused on the development and commercialization of
ARIKACE®, or liposomal amikacin for inhalation, for at least two
identified orphan patient populations: patients with
non-tuberculous mycobacteria (NTM) lung infections and cystic
fibrosis (CF) patients with Pseudomonas
aeruginosa lung infections. For more information, please
visit http://www.insmed.com.
Forward-looking Statements This release contains forward-looking
statements. Words, and variations of words, such as "intend,"
"expect," "will," "anticipate," "believe," "continue," "propose"
and similar expressions are intended to identify forward-looking
statements. Investors are cautioned that such statements in
this release, including statements relating to the status, results
and timing of clinical trials and clinical data, the anticipated
benefits of Insmed's products, the anticipated timing of regulatory
submissions, and the ability to obtain required regulatory
approvals, bring products to market and successfully commercialize
products constitute forward-looking statements that involve risks
and uncertainties that could cause actual results to differ
materially from those in the forward-looking statements. Such
risks and uncertainties include, without limitation, failure or
delay of European, Canadian, U.S. Food and Drug Administration and
other regulatory reviews and approvals, competitive developments
affecting the Company's product candidates, delays in product
development or clinical trials or other studies, patent disputes
and other intellectual property developments relating to the
Company's product candidates, unexpected regulatory actions, delays
or requests, the failure of clinical trials or other studies or
results of clinical trials or other studies that do not meet
expectations, the fact that subsequent analyses of clinical trial
or study data may lead to different (including less favorable)
interpretations of trial or study results or may identify important
implications of a trial or study that are not reflected in
Company's prior disclosures, and the fact that trial or study
results or subsequent analyses may be subject to differing
interpretations by regulatory agencies, the inability to
successfully develop the Company's product candidates or receive
necessary regulatory approvals, inability to make product
candidates commercially successful, changes in anticipated
expenses, changes in the Company's financing requirements or
ability raise additional capital, and other risks and challenges
detailed in the Company's filings with the U.S. Securities and
Exchange Commission, including its Annual Report on Form 10-K for
the year ended December 31, 2012. Investors are cautioned not
to place undue reliance on any forward-looking statements that
speak only as of the date of this news release. The Company
undertakes no obligation to update these forward-looking statements
to reflect events or circumstances or changes in its
expectations.
Contacts: LHA Anne Marie Fields Senior Vice President
212-838-3777 afields@lhai.com Bruce Voss Managing Director
310-691-7100 bvoss@lhai.com
Insmed (NASDAQ:INSM)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Insmed (NASDAQ:INSM)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024